MUMPSVAX SUMMARY
MUMPSVAX * (Mumps Virus Vaccine Live) is a live virus vaccine for vaccination against mumps.
MUMPSVAX is indicated for vaccination against mumps in persons 12 months of age or older.
|
|
NEWS HIGHLIGHTS
Published Studies Related to Mumpsvax (Mumps Vaccine)
Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial. [2011.06.06]
Co-administration of meningococcal ACWY-tetanus toxoid conjugate vaccine (ACWY-TT) with MMRV vaccine was investigated in 1000 12-23-month old children randomized (3:3:1:1) to receive co-administered ACWY-TT+MMRV, or a single dose of ACWY-TT, MMRV or MenC-CRM(197)... This study has been registered at www.clinicaltrials.gov NCT00474266.
Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses. [2011.05.17]
BACKGROUND: The MMRV combination vaccine, Priorix-Tetra, is currently licensed in several European countries using a two-dose schedule in infants aged >/=9 months, with a preferred 6-week to 3-month interval between doses. This study was undertaken to generate safety and immunogenicity data for two doses of MMRV vaccine administered according to dose schedules using the shortest permitted interval of 4 weeks versus a longer interval of 12 months, which would allow flexible adaptation to local immunization calendars... CONCLUSIONS: Two doses of MMRV vaccine administered in the second year of life elicited adequate immunogenicity and were well-tolerated whether administered with a dose interval of 4 weeks or 12 months. Copyright (c) 2011. Published by Elsevier Ltd.
Safety and immunogenicity of coadministering a combined meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine with 7-valent pneumococcal conjugate vaccine and measles, mumps, and rubella vaccine at 12 months of age. [2011.03]
The coadministration of the combined meningococcal serogroup C conjugate (MCC)/Haemophilus influenzae type b (Hib) vaccine with pneumococcal conjugate vaccine (PCV7) and measles, mumps, and rubella (MMR) vaccine at 12 months of age was investigated to assess the safety and immunogenicity of this regimen compared with separate administration of the conjugate vaccines...
Intralesional immunotherapy of common warts: successful treatment with mumps, measles and rubella vaccine. [2010.10]
BACKGROUND: Despite numerous therapeutic modalities reported in the literature, treatment of common warts remains a continuing challenge and there is no universal consensus about optimal treatment. Recently, intralesional immunotherapy by different antigens has proved efficacy in the treatment of different types of warts. OBJECTIVE: To evaluate the efficacy and safety of intralesional mumps, measles and rubella (MMR) vaccine in the treatment of common warts... CONCLUSIONS: Intralesional immunotherapy by MMR vaccine is a promising effective and safe treatment modality for common warts, particularly the multiple ones. (c) 2010 The Authors. Journal of the European Academy of Dermatology and Venereology (c) 2010 European Academy of Dermatology and Venereology.
Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months. [2010.06]
BACKGROUND: A booster dose of pneumococcal conjugate vaccine may be administered at the same age as measles-mumps-rubella-varicella (MMRV) vaccination. This study examined the safety, reactogenicity, and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with MMRV vaccine... CONCLUSIONS: PHiD-CV and MMRV vaccine can be coadministered without compromising the safety and immunogenicity profiles of either vaccine.
Clinical Trials Related to Mumpsvax (Mumps Vaccine)
A Phase I, Safety Study of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Children [Recruiting]
Mumps is an acute infectious respiratory disease caused by the mumps virus (MuV), which
occurs mainly in children and adolescents. Its main clinical symptoms were parotid gland
suppurative swelling and pain with fever. The pathological changes and harm caused by mumps
was not only confined to the parotid gland, on the contrary, the social harm caused by
serious complications cannot be ignored. As mumps is a vaccine-preventable infectious
disease, vaccination is a fundamental strategy for controlling mumps. So far, there are 13
genotypes of MuV. Based on the analysis of molecular epidemiology, the main epidemic strain
of MuV in China was the F genotype. The commonly used vaccine strains represented only a
small number of known genotypes, e. g. Jeryl-Lynn (JL) and Rubini strains, which belong to
type A, Urabe strain belongs to type B, and L-Zagreb strains belongs to type D. Virus seed
of Live Attenuated Mumps Vaccine (Human diploid cell) developed by the institute was SP-A
strain, which was the first separation and preparation of the attenuated mumps viruses in
China. SP-A belongs to F genotype, which was the domestic epidemic genotype. In addition,
the cell substrate prepared for vaccine was human diploid cell (KMB-17 strain), which is
much safer to use. The preliminary test results showed that the vaccine possessed good
immunogenicity and good antigenic cross-reactivity. The application of this vaccine will
provide more effective means to prevent and control of mumps epidemic.
A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age [Active, not recruiting]
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases [No longer recruiting]
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases [Completed]
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases [Completed]
|
|
|
|
Page last updated: 2011-12-09
|
